Structural and glycation site changes of albumin in diabetic patient with very high glycated albumin

Kisugi, Reiko; Kouzuma, Takuji; Yamamoto, Tamotsu; Akizuki, Setsuko; Miyamoto, Hirokuni; Someya, Yasutoshi; Yokoyama, Jun′ichi; Abe, Ikurho; Hirai, Noriyuki; Ohnishi, Akihiro

doi:10.1016/j.cca.2007.04.001

Cited by 79 publications

(48 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The molecular form of the glycosylated albumin is highly variable [19] and therefore results were reported in nonmass units. Previous studies usually measured GA using an A strength of this study is that we used a large number of glucose readings per individual over a 3-month period to establish glycemic control.…”

Section: Discussionmentioning

confidence: 99%

Brief communication (Original). Correlation of glycated albumin with self blood glucose monitoring in diabetic patients on hemodialysis taking erythropoietin

2014

View full text Add to dashboard Cite

Background: Serum glycated albumin (GA) is a marker of glycemic control in diabetic renal patients, but studies were limited by the use of few random glucose values to define glycemic control. Objectives: To determine whether GA correlated with self blood glucose monitoring is better than HbA1c in hemodialyzed diabetic patients taking erythropoietin. Methods: This was a cross-sectional study of diabetic patients on hemodialysis with and without erythropoietin. GA was measured by ELISA and HbA1c by ion-exchange HPLC. GA was reported as the GA/albumin ratio where albumin was measured using bromocresol green. The average capillary blood glucose level over the preceding three months (CBG) was calculated from self-reported daily prebreakfast, prelunch, and prebed glucose meter readings. Results: Thirty-four patients were recruited; 18 were taking erythropoietin (6000 units per week) and 16 had never received erythropoietin. HbA1c correlated poorly with CBG in patients taking erythropoietin (r = -0.014, P = 0.96) compared with patients without erythropoietin (r = 0.579, P = 0.02). The correlation of GA/albumin ratio with CBG in the erythropoietin group (r = 0.612, P = 0.007) was similar to the nonerythropoietin group (r = 0.854, P < 0.001). The slope for HbA1c versus CBG was 2.8-fold greater in patients without erythropoietin compared with those taking erythropoietin. There was no significant difference in the slopes for GA/albumin ratio versus CBG between the two patient groups (P > 0.05). Conclusion:In diabetic patients on hemodialysis and taking low doses of erythropoietin, GA/albumin is a better marker of glycemic control than HbA1c.

show abstract

Section: Discussionmentioning

confidence: 99%

Brief communication (Original). Correlation of glycated albumin with self blood glucose monitoring in diabetic patients on hemodialysis taking erythropoietin

2014

View full text Add to dashboard Cite

show abstract

“…14 The patient with an HbA 1c value of 19.9% visited the emergency department complaining of fatigue and had a BG of 20.6 mmol/L and GA of 98.5%. 13 We cite these two articles as examples of extremely high HbA 1c levels associated with diabetes. However, these two patients exhibited typical diabetes-associated symptoms and higher BG and GA concentrations compared with our case.…”

Section: Discussionmentioning

confidence: 99%

A patient with acute lymphoblastic leukaemia presenting with an extremely high level (21.0%) of HbA_1c

et al. 2011

View full text Add to dashboard Cite

A 52-year-old Japanese woman was referred to our hospital because of fever and coxalgia. She had a white blood cell count of 241 Â 10 2 /mL with 59.6% blasts, which had a high nuclear/cytoplasmic ratio and variably condensed nuclear chromatin.Flow cytometry and chromosomal analysis of bone marrow cells indicated positive findings of CD10, CD19, CD34, HLA-DR antigens and t(9; 22)(q34; q11.2), respectively. No rearrangements of bcr/abl in peripheral blood neutrophils were found by fluorescence in situ hybridization, suggesting that she had B-acute lymphoblastic leukaemia with Ph chromosome. Blood glucose and HbA 1c (glycated haemoglobin) levels on admission were 23.4 mmol/L and 21.0%, respectively. The results of 1.5 anhydro-D-glucitol and glycoalbumin tests revealed that she certainly had diabetes mellitus (DM). Insulin therapy was initiated. Her high level of HbA 1c also suggested the possibility that the patient suffered from haemoglobinopathies in addition to DM. Sequencing analyses of a1-, a2-and b-globin genes were all normal. The patient achieved complete remission (CR) by one month after her first course of chemotherapy, and the HbA 1c level decreased to 10.4% following insulin therapy and chemotherapy, which were initiated when she attained CR. Her extremely high HbA 1c level was due mainly to DM. Also, suppression of erythropoiesis by proliferation of leukaemic cells and latent iron deficiency might have partially contributed to the increased HbA 1c . This could result in a transient but extremely high HbA 1c level. To our knowledge, this is the first report of an acute leukaemia patient who expressed an extremely high level of HbA 1c .

show abstract

“…The main Amadori adduct formed is fructoselysine, a reaction between glucose and lysine, which may occur on 59 lysine sites present in albumin (18). However, lysine 525 has been identified as the largest albumin glycation site, which is evidenced both in vivo and in vitro experiments (23,24). The set of ketamines formed by non-enzymatic glycation of proteins is chemically called "fructosamine".…”

Section: Biochemical Characteristics Of Ga and Biological Impact Of Gmentioning

confidence: 99%

Glycated albumin: a potential biomarker in diabetes

Freitas

Ehlert

Camargo

2017

Arch. Endocrinol. Metab.

146

103

View full text Add to dashboard Cite

Diabetes mellitus (DM) is a chronic and metabolic disease that presents a high global incidence. Glycated hemoglobin (A1C) is the reference test for long-term glucose monitoring, and it exhibits an association with diabetic chronic complications. However, A1C is not recommended in clinical situations which may interfere with the metabolism of hemoglobin, such as in hemolytic, secondary or iron deficiency anemia, hemoglobinopathies, pregnancy, and uremia. The glycated albumin (GA) is a test that reflects short-term glycemia and is not influenced by situations that falsely alter A1C levels. GA is the higher glycated portion of fructosamine. It is measured by a standardized enzymatic methodology, easy and fast to perform. These laboratory characteristics have ensured the highlight of GA in studies from the last decade, as a marker of monitoring and screening for DM, as well as a predictor of long-term outcomes of the disease. The aim of this review was to discuss the physiological and biochemistry characteristics of the GA, as well as its clinical utility in DM. Arch Endocrinol Metab.2017;61(3):296-304.

show abstract

Structural and glycation site changes of albumin in diabetic patient with very high glycated albumin

Cited by 79 publications

References 17 publications

Brief communication (Original). Correlation of glycated albumin with self blood glucose monitoring in diabetic patients on hemodialysis taking erythropoietin

Brief communication (Original). Correlation of glycated albumin with self blood glucose monitoring in diabetic patients on hemodialysis taking erythropoietin

A patient with acute lymphoblastic leukaemia presenting with an extremely high level (21.0%) of HbA_1c

Glycated albumin: a potential biomarker in diabetes

Contact Info

Product

Resources

About

Structural and glycation site changes of albumin in diabetic patient with very high glycated albumin

Cited by 79 publications

References 17 publications

Brief communication (Original). Correlation of glycated albumin with self blood glucose monitoring in diabetic patients on hemodialysis taking erythropoietin

Brief communication (Original). Correlation of glycated albumin with self blood glucose monitoring in diabetic patients on hemodialysis taking erythropoietin

A patient with acute lymphoblastic leukaemia presenting with an extremely high level (21.0%) of HbA1c

Glycated albumin: a potential biomarker in diabetes

Contact Info

Product

Resources

About

A patient with acute lymphoblastic leukaemia presenting with an extremely high level (21.0%) of HbA_1c